A study from Karolinska Institutet shows that patients with type 2 diabetes who have high blood sugar levels, low body weight, or have previously had ketoacidosis have an increased risk of serious side effects when treated with SGLT2 inhibitors, which persists throughout the treatment period. (translated)












